注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Sarepta Therapeutics Inc是一家商業階段的生物製藥公司。該公司專注於幫助患者發現和開發核糖核酸(RNA)靶向療法、基因療法和其他用於治療罕見疾病的基因療法。其正在開發治療各種疾病和障礙的候選藥物,包括杜氏肌營養不良症(Duchenne)、肢帶型肌營養不良症(LGMDs)和其他神經肌肉和中樞神經系統(CNS)相關疾病。其商業產品EXONDYS 51(eteplirsen)注射劑、VYONDYS 53(golodirsen)注射劑和AMONDYS 45(casimersen)注射劑用於治療DMD患者,這些患者有確認的DMD基因突變,可以跳過51外顯子、53外顯子和45外顯子。該公司還包括40多個處於發現、臨床前和臨床開發不同階段的項目。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Douglas S. Ingram | 58 | 2017 | President, CEO & Director |
M. Kathleen Behrens | 69 | 2009 | Independent Chairwoman |
Beverly L. Davidson | - | 2015 | Member of Strategic & Scientific Advisory Board |
Hans Wigzell | 83 | 2010 | Chairman of Corporate Strategy Board & Independent Non-Employee Director |
Louis M. Kunkel | - | 2015 | Member of Strategic & Scientific Advisory Board |
Kenneth H. Fischbeck | - | 2017 | Member of Strategic & Scientific Advisory Board |
Matthew Wood | - | 2017 | Member of Strategic & Scientific Advisory Board |
Steven Gray | - | 2019 | Member of Scientific Advisory Board |
Angela J. Russell | - | 2020 | Member of Scientific Advisory Board |
Carsten Bonnemann | - | 2019 | Member of Scientific Advisory Board |
Kay Davies | - | 2019 | Member of Scientific Advisory Board |
Annemieke Aartsma-Rus | - | 2019 | Member of Scientific Advisory Board |
Joy A. Cavagnaro | - | 2019 | Member of Scientific Advisory Board |
Stephen L. Mayo | 60 | 2021 | Independent Director |
Michael Chambers | 48 | 2022 | Independent Director |
Kathryn J. Boor | 64 | 2022 | Independent Director |
Claude Nicaise | 70 | 2015 | Independent Non-Employee Director |
Richard Jon Barry | 64 | 2015 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核